Hot Investor Mandate: USA-Based Investment Firm Actively Seeks Therapeutics Opportunities Across All Modalities and Indications, Investing Up to $20M

24 Feb

An investment firm based in the USA is interested in therapeutics companies that are 12-18 months from IND, although the firm may consider earlier-stage companies which are first in class. The firm invests in assets that have global opportunities with ticket size from $0.5-20M, depending on the opportunity and stage of the asset. The firm is actively involved in-licensing novel first in class assets.

Within therapeutics, the firm is agnostic to modality and indication. The firm does tend to invest more in oncology and regenerative medicine, but more due to a larger amount of deal flow in these areas.

The firm is an active investor, and will take a board seat in all of their portfolio companies. While they prefer to lead, the firm will co-invest with other partners. The firm makes use of their deep drug development expertise to advance their portfolio companies toward clinic.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: